UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000046043 |
|---|---|
| Receipt number | R000052553 |
| Scientific Title | Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study. |
| Date of disclosure of the study information | 2021/11/11 |
| Last modified on | 2022/05/29 10:45:17 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study.
Acronym
Anti-CD20-Ab mRNA COVID19 vaccine study
Scientific Title
Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study.
Scientific Title:Acronym
Anti-CD20-Ab mRNA COVID19 vaccine study
Region
| Japan |
Condition
Condition
B cell non-Hodgkin lymphoma, Post-transplant Lymphoproliferative Disorders, Idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this study is to evaluate the positivity of SARS-CoV-2 IgG antibody titer after completion of BNT162b2, mRNA-1273, and ChAdOx1-S vaccination in patients with hematological diseases who have received rituximab and obinutuzumab, and to evaluate the post-vaccination adverse reactions that occurred when these vaccines were administered. The purpose of this study was to evaluate the positive rate of SARS-CoV-2 IgG antibody titer after completion of ChOx1-S vaccination, and to evaluate the post-vaccination adverse reactions that occurred when these vaccines were given.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The primary endpoint will be the rate of SARS-CoV-2 IgG antibody positivity.
Key secondary outcomes
Secondary endpoints will be SARS-CoV-2 IgG antibody titer, peripheral blood lymphocyte fraction, IgG, IgA, IgM, and presence and content of post-vaccination adverse reactions.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Adult patients who have received rituximab/obinutuzumab for hematological diseases (B-cell non-Hodgkin's lymphoma, B-cell lymphoproliferative disease under immunosuppressive conditions, chronic idiopathic thrombocytopenic purpura, acquired thrombocytopenic purpura)
2) Patients who are willing to receive SARS-CoV-2 vaccination initiated by the Japanese government or local government.
3) Patients who have given written consent to participate in the study.
Key exclusion criteria
1) Patients whom the principal investigator or sub-investigator judges to be inappropriate for participation in the study
2) Patients who have previously received rituximab for non-hematological diseases (polyangiitis granulomatosa, microscopic polyangiitis, refractory nephrotic syndrome)
3) Patients with a history of COVID-19
4) Patients with a history of or coexistence with autoimmune diseases other than chronic idiopathic thrombocytopenic purpura (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic scleroderma, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis and related diseases, vasculitis syndrome, inflammatory bowel disease, Guillain-Barre syndrome, multiple sclerosis, neuromyelitis optica)
5) Patients who are unable to communicate with others
Target sample size
150
Research contact person
Name of lead principal investigator
| 1st name | Takayuki |
| Middle name | |
| Last name | Ishikawa |
Organization
Kobe City Medical Center General Hospital
Division name
Department of Hematology
Zip code
650-0047
Address
2-1-1 Minatojima-minami-machi Chuo-ku Kobe City Hyogo Japan
TEL
078-302-4321
ishikawa@kcho.jp
Public contact
Name of contact person
| 1st name | Masashi |
| Middle name | |
| Last name | Nishikubo |
Organization
Kobe City Medical Center General Hospital
Division name
Department of Hematology
Zip code
650-0047
Address
2-1-1 Minatojima-minami-machi Chuo-ku Kobe City Hyogo Japan
TEL
078-302-4321
Homepage URL
masashi_nishikubo@kcho.jp
Sponsor or person
Institute
Kobe City Medical Center General Hospital
Institute
Department
Personal name
Funding Source
Organization
Kobe City Medical Center General Hospital, Department of Hematology
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kobe City Medical Center General Hospital
Address
2-1-1 Minatojima-minami-machi Chuo-ku Kobe City Hyogo Japan
Tel
078-302-5176
rinken@kcho.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 11 | Month | 11 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
152
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2021 | Year | 05 | Month | 24 | Day |
Date of IRB
| 2021 | Year | 06 | Month | 04 | Day |
Anticipated trial start date
| 2021 | Year | 06 | Month | 04 | Day |
Last follow-up date
| 2022 | Year | 07 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Nothing particular
Management information
Registered date
| 2021 | Year | 11 | Month | 11 | Day |
Last modified on
| 2022 | Year | 05 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052553
